Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ biosynthesis
Breast Neoplasms
/ enzymology
Disease-Free Survival
Female
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Group II Phospholipases A2
/ biosynthesis
Humans
Middle Aged
Neoplasm Proteins
/ biosynthesis
Prospective Studies
Survival Rate
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
29
3
2020
medline:
15
10
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this group of enzymes are utilized in liposomal drug delivery of chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target in itself, and as a prognostic marker. The expression of sPLA2-IIa in breast cancer has not been examined extensively, and never using immunohistochemistry. We sought to investigate the expression of sPLA2-IIa in a cohort of advanced breast cancer patients with correlation to known clinicopathologic risk factors and survival. Material from 525 breast cancer patients (426 primary tumors and 99 metastases or local recurrences) was examined for sPLA2-IIa expression using immunohistochemistry. Out of these, 262 showed expression of sPLA2-IIa. We found that there was no correlation to clinicopathologic characteristics, and no impact of sPLA2-IIa expression on prognosis. However, we found that a large proportion of patients in our study had high levels of sPLA2-IIa expression, and that sPLA2-IIa was equally expressed in primary tumors and metastases. These findings may be significant in the future development of liposomal drug delivery or targeted sPLA2-IIa treatment.
Identifiants
pubmed: 32217848
doi: 10.1097/PAI.0000000000000854
pii: 00129039-202101000-00014
doi:
Substances chimiques
Biomarkers, Tumor
0
Neoplasm Proteins
0
Group II Phospholipases A2
EC 3.1.1.4
PLA2G2A protein, human
EC 3.1.1.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e5-e9Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52:56–73.
Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem. 2008;77:495–520.
Brglez V, Lambeauc G, Petan T. Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie. 2014;107:114–123.
Kupert E, Anderson M, Liu Y, et al. Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer. 2011;11:513.
Wang M, Hao F-Y, Wang J-G, et al. Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2014;18:2648–2654.
Oleksowicz L, Liu Y, Bracken RB, et al. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate. 2012;72:1140–1149.
He H-L, Lee Y-E, Shiue Y-L, et al. PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy. Histopathology. 2015;66:991–1002.
Yu JA, Mauchley D, Li H, et al. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg. 2012;144:1185–1191.
Pedada SR, Yarla NS, Tambade PJ, et al. Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents. Eur J Med Chem. 2016;112:289–297.
Lee S, Kim D, Kang J, et al. Surfactant protein B suppresses lung cancer progression by inhibiting secretory phospholipase A2 activity and arachidonic acid production. Cell Physiol Biochem. 2017;42:1684–1700.
Halpern AL, Kohtz PD, Rove JY, et al. Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma. Mol Cell Biochem. 2019;456:145–156.
Petrelli F, Barni S, Bregni G, et al. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. Breast Cancer Res Treat. 2016;160:425–437.
Østrem RG, Parhamifar L, Pourhassan H, et al. Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo. J Control Release. 2017;262:212–221.
Menschikowski M, Hagelgans A, Schuler U, et al. Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers. Pathol Oncol Res. 2013;19:839–846.
Pourhassan H, Clergeaud G, Hansen AE, et al. Revisiting the use of sPLA2-sensitive liposomes in cancer therapy. J Control Release. 2017;261:163–173.
Fouladi F, Steffen KJ, Mallik S. Enzyme-responsive liposomes for the delivery of anticancer drugs. Bioconjug Chem. 2017;28:857–868.
Lassen U.Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours [ClinicalTrials.gov]; 2013. Available at: https://clinicaltrials.gov/ct2/show/NCT01861496?term=liplacis&rank=1 . Accessed May 22, 2019.
Mannello F, Qin W, Zhu W, et al. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Res Treat. 2008;111:209–218.
Qu J, Zhao X, Wang J, et al. Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer. Oncol Lett. 2018;15:5236–5242.
Xu S, Chen C, Wang W-X, et al. Crucial role of group IIA phospholipase A2 in pancreatitis-associated adrenal injury in acute necrotizing pancreatitis. Pathol Res Pract. 2010;206:73–82.
Can Dijk A, Krijnen PAJ, Vermond RA, et al. Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction. Apoptosis. 2009;14:753–763.
Brglez V, Pucer A, Pungerčar J, et al. Secreted phospholipases A2 are differentially expressed and epigenetically silenced in human breast cancer cells. Biochem Biophys Res Commun. 2014;445:230–235.
Dong Z, Meller J, Succop P, et al. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells. Int J Oncol. 2014;45:978–984.